Biotechnology from bench to business

• Follow GEN on:
• Login | Register | Subscribe

• ADME/Tox
• Automation
• Bioprocess Scale-Up
• Bioreactors
• Biosimilars
• Cell Culture
• Cell-Based Assays
• Contract Manufacturing
• Gene Therapy
• High-Throughput Screening
• Immunoassay
• Induced Pluripotent Stem Cells
• Informatics
• Liquid Handling
• Protein Characterization
• Protein Detection
• Regenerative Medicine
• RNAi/siRNA
• Stem Cells
• Western Blot

• GEN Articles

• More »

• Feature Articles: Exploiting miRNA’s Potential for Diagnostics and Drugs
  
• Tutorials: Automated miRNA Isolation Using SPRI
  Changing Binding Conditions Allows for Recovery from Cell Culture, FFPE, and Tissue Samples
• Feature Articles: Clinical Application of miRNAs a Ways Off
  When and If Its Time Comes, Prognostic Tests Will Likely Be First
• BioMarket Trends: Hotspots of miRNA Research Activity
  
• Feature Articles: Capitalizing on miRNA Research
  

• Insight & Intelligence™

• More »

• Clinical Application of miRNAs Remains a Ways Off
  July 19, 2012
  When and if its time comes, prognostic tests will likely be first.
• Chasing the Therapeutic Potential of miRNAs
  September 10, 2009
  The spate of deal-making, new company formations, and patent applications have set up miRNAs as the next wave in nucleic acid-based drugs.

• GEN News Highlights

• More »

• Mirna Initiates PI Trial for miRNA Candidate Cancer Drug
  
• miRNA: The Key to Losing Those Love Handles?
  
• Gene Discovery Portends Schizophrenia Paradigm Shift
  
• Transgenic Cow Makes Hypoallergenic Milk
  
• New Target for Obesity-Related Disorders
  

• GEN Podcasts

• More »

• miRNA BIOMARKERS FOR DRUG-INDUCED LIVER INJURY
  - Interview with David Galas, Ph.D., Senior Vice President of Strategic Partnerships, Institute for Systems Biology
• SINGLE miRNA MOLECULE CONTROLS BLOOD VESSEL DEVELOPMENT
  - Interview with Jason Fish, Ph.D., Postdoctoral Fellow in the Laboratory of Deepak Srivastava at the Gladstone Institute of Cardiovascular Disease
• miRNAs AND CANCER
  - Interview with George Calin, M.D., Ph.D., Associate Professor, Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center

• New Products

• More »

Sigma-Aldrich microRNA Inhibitors Each Mission® synthetic and lentiviral microRNA inhibitor is designed for the long-term suppression of any miRNA endogenous to humans or mice, using an algorithm that evaluates all possible sequences for the design predicted to best maintain t